Spero surges as GSK-partnered UTI candidate succeeds in late-stage trial

1 day ago 1

Healthcare
On the Move

$100 Growth Rolling Banknote, Green Arrow, Object + Shadow Clipping Path

Nano-cap U.S. biotech Spero Therapeutics (NASDAQ:SPRO) added ~255% in the premarket on Wednesday after the company and its partner GSK (NYSE:GSK) announced that tebipenem HBr, their oral treatment for urinary tract infections, hit the main goal in a pivotal

Recommended For You

Read Entire Article

Spero surges as GSK-partnered UTI candidate succeeds in late-stage trial

Recommended For You

Related

Femasys announces public offering, concurrent private placem...

Inside the $400 million Coinbase breach: An Indian call cent...

Yatra Online reports Q4 results

Beam receives Orphan Drug status for genetic disorder asset ...

Hafnia files shelf registration for mixed securities offerin...

Zscaler Q3 revenue increases 23% as its AI security offering...

Costco outpaces Walmart and Target again in the U.S.

Starz Entertainment Corp. reports Q4 results

Digital Asset Acquisition announces separate trading of its ...

SA analyst downgrades: TSLA, AVGO, PM, FUTU, GPOR

American Eagle slumps after reporting another quarterly loss...

Federal appeals court issues stay on Trump tariffs ruling

Sonder Holdings receives notification of deficiency from Nas...

Stocks lose steam as courts swing back and forth on Trump ta...

Ambarella Non-GAAP EPS of $0.07 beats by $0.03, revenue of $...

Trump wins emergency stay in high-stakes tariff battle

SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM

PCE inflation seen ticking up in April, as tariff effects fi...

Baker Hughes, C3 AI to expand joint venture through 2028

A little-known federal court threw a giant monkey wrench int...

Trending

Popular

نشا برنج در گیلان

اعطای نشان افتخار تیپ چهل ارتش به دوخانواده شهید خدمت